Since NFκB is able to regulate more than 150 genes, and is able to functionally orchestrate many steps in carcinogenesis, tumor progression and metastasis, it is important to delineate the efficacy of potential EGFR-TK inhibitors that target the NFκB-dependent HNSCC cell survival advantage. Here, EGFR is linked to head and neck squamous cell carcinoma.